Abeona therapeutics announces upcoming data presentations at the society for pediatric dermatology 45th annual meeting

New york and cleveland, june 18, 2020 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to its clinical program for recessive dystrophic epidermolysis bullosa (rdeb) will be presented at the upcoming society for pediatric dermatology (spd) 45th annual meeting, to be held virtually during july 10-12, 2020. rdeb is a rare connective tissue disorder without an approved treatment, in which patients suffer from severe epidermal wounds that severely impact their lives.
ABEO Ratings Summary
ABEO Quant Ranking